Sugar Maple Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Sugar Maple Asset Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$346K	Buy	83,060 +25,000	+43%	+$105K	0.22%	69
2026 Q1	$241K	Buy	58,060 +3,210	+6%	+$13K	0.15%	77
2025 Q4	$354K	Buy	54,850 +42,850	+357%	+$267K	0.24%	62
2025 Q3	$67.1K	Hold	12,000	–	–	0.05%	79
2025 Q2	$39.7K	Sell	12,000 -17,500	-59%	-$50.2K	0.03%	74
2025 Q1	$85.5K	Buy	+29,500	New	+$89.3K	0.07%	64

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Sugar Maple Asset Management's AQST Position: Q2 2026 in Review

Sugar Maple Asset Management increased its Aquestive Therapeutics (AQST) stake by 43% in Q2 2026, buying an estimated $105K and bringing the position to 83,060 shares worth $346K. The position accounts for 0.22% of the portfolio, ranked #69.

Sugar Maple Asset Management first reported a position in AQST in Q1 2025 and has held it in 6 quarters since. The position peaked at $354K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Sugar Maple Asset Management held 83,060 shares of Aquestive Therapeutics worth $346K as of Q2 2026.
Sugar Maple Asset Management bought 25,000 Aquestive Therapeutics shares in Q2 2026, an estimated $105K.
Aquestive Therapeutics made up 0.22% of Sugar Maple Asset Management's portfolio in Q2 2026, its #69 holding.
Sugar Maple Asset Management first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 6 quarters since.
Sugar Maple Asset Management's Aquestive Therapeutics position peaked at $354K in Q4 2025.
185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Sugar Maple Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.